v3.26.1
Schedule of Segment Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Segment Reporting Information [Line Items]    
Revenue $ 1,123 $ 43
Net loss (11,168) (8,814)
Other Operating Segment [Member]    
Segment Reporting Information [Line Items]    
Revenue 1,123 43
Other research and development expenses [1] 396 161
Non-program expenses [2] 4,660 3,556
Personnel compensation and related expenses, including share-based compensation 4,768 4,078
Other segment items [3] (1,342) (2,156)
Net loss 11,168 8,814
Other Operating Segment [Member] | Clinical Trial Studies [Member]    
Segment Reporting Information [Line Items]    
Program expenses [1] 3,016 2,800
Other Operating Segment [Member] | Manufacturing Renovocath [Member]    
Segment Reporting Information [Line Items]    
Program expenses [1] $ 793 $ 418
[1] Includes external research expenses, clinical studies, manufacturing development and non-recurring engineering costs, professional and consulting, regulatory, and trade shows.
[2] Includes selling, general and administrative expenses for professional and consulting expenses, audit fees, board fees, legal expenses, insurance expenses, travel, and other office expenses.
[3] Includes Interest income and interest expense and gain recognized on the fair value of common stock warrant liability.